Liminal BioSciences sells plasma-derived therapeutics manufacturing facility
The consideration received by Liminal for PBP was USD 5 million, which was received upon closing, subject to adjustments.
Sales & Marketing
LAVAL and CAMBRIDGE — Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, announced on Jul. 12 that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. The manufacturing facility is operated through Liminal BioSciences’ subsidiary, Prometic Bioproduction Inc.
The consideration received by Liminal for PBP was USD 5 million, which was received upon closing, subject to adjustments. Liminal will also be entitled to receive 70% of the net proceeds from a sale of the Rare Pediatric Disease Priority Review Voucher by its subsidiary, Prometic Biotherapeutics Inc., which would be payable to Liminal prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT. PBT is the holder of the biological license application for Ryplazim® (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). The Second Closing is subject to the fulfilment of certain conditions precedent, including the sale of the PRV by PBT.
Liminal BioSciences is a biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases of unmet medical need, primarily related to fibrosis, including respiratory, liver and kidney diseases.